Cite
HARVARD Citation
Mosenzon, O. et al. (2019). Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet. 7 (8), pp. 606-617. [Online].